Innoviva (INVA) Research & Development (2010 - 2026)
Innoviva (INVA) posted Research & Development of $5.19 million for Q2 2026, down 35.0% from $7.98 million a year earlier and down 1.0% from the prior quarter.
Powered by 
Analysis
Innoviva (INVA) Research & Development (2010 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Research & Development at Innoviva was $28.66 million, up 46.2% year-over-year; for FY2025, it was $30.6 million, up 124.1% from FY2024.
- Annual Research & Development shows a five-year compound annual growth rate of 76.5% (FY2020 to FY2025).
- In prior years, Innoviva's Research & Development was $13.65 million in FY2024 (-59.7%), $33.92 million in FY2023 (-18.1%), $41.43 million in FY2022 and $576,000 in FY2021 (-67.8%).
- Quarterly Research & Development has run from a low of $40,000 in Q4 2021 to a high of $14.99 million in Q2 2023 over five years.
- On a year-over-year basis, Research & Development increased in five of the last six quarters, with growth averaging 86.4%.
- The strongest year-over-year quarter for Research & Development in the past five years was Q3 2025, with growth of 285.0%; the weakest was Q2 2024, with a decline of 82.9%.
- According to Business Quant data, Research & Development for the three prior quarters was $5.24 million (Q1 2026), $4.56 million (Q4 2025) and $13.67 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Innoviva | 1.54 Bn | -748.67 Mn | 90.62 Mn | 5.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.19 Mn |
| Mar 31, 2026 | 5.24 Mn |
| Dec 31, 2025 | 4.56 Mn |
| Sep 30, 2025 | 13.67 Mn |
| Jun 30, 2025 | 7.98 Mn |
| Mar 31, 2025 | 4.40 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 3.55 Mn |
| Jun 30, 2024 | 2.56 Mn |
| Mar 31, 2024 | 3.88 Mn |
| Sep 30, 2023 | 3.99 Mn |
| Jun 30, 2023 | 14.99 Mn |
| Mar 31, 2023 | 12.59 Mn |
| Sep 30, 2022 | 11.73 Mn |
| Jun 30, 2022 | 13.88 Mn |
| Mar 31, 2022 | 5.84 Mn |
| Dec 31, 2021 | 40,000.00 |
| Sep 30, 2021 | 449,000.00 |
| Jun 30, 2021 | 38,000.00 |
| Mar 31, 2021 | 49,000.00 |
API Access
Innoviva Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=INVA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "INVA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=INVA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();